# US 8,541,564 B2 · Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 8,541,564 B2 - Document ID: US8541564B2 - Status: Granted - Kind: B2 - Application number: 13/480,526 - Filed: 2012-05-25 - Published: 2012-12-06 - Granted: 2013-09-24 - Earliest claimed: 2011-06-01 - Assignees: Morehouse School of Medicine - Applicants: James W. Lillard, Jr. - Inventors: James W. Lillard, Jr. - Web page: https://patentgrep.com/patent/US8541564B2 ## CPC - C07K 16/2866: {against receptors for cytokines, lymphokines, interferons} - A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system - A61P 9/00: Drugs for disorders of the cardiovascular system - A61P 11/00: Drugs for disorders of the respiratory system - A61P 13/00: Drugs for disorders of the urinary system - A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives - A61P 17/00: Drugs for dermatological disorders - A61P 19/00: Drugs for skeletal disorders - A61P 21/00: Drugs for disorders of the muscular or neuromuscular system - A61P 25/00: Drugs for disorders of the nervous system - A61P 27/02: Ophthalmic agents - A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] - A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics - A61P 31/04: Antibacterial agents - A61P 35/00: Antineoplastic agents - A61P 35/02: specific for leukemia - A61P 37/02: Immunomodulators - C07K 14/521: {Chemokines} - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto - Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE ## Abstract This application is directed to chemokine-immunoglobulin fusion polypeptides and chemokine-polymer conjugates. The fusion polypeptides and conjugates can be used for treating chemokine receptor-mediated disorders and modulating inflammation, inflammatory cell motility, cancer cell motility, or cancer cell survival. ## Claims ### Claim 1 An isolated chemokine-immunoglobulin fusion polypeptide, comprising a chemokine moiety from human CLXCL11 and an immunoglobulin moiety from the constant region of human IgG1 (IgG1Fc), wherein the chemokine-immunoglobulin fusion polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:67, SEQ ID NO:68 and SEQ ID NO:69. ### Claim 2 (depends on 1) The isolated chemokine-immunoglobulin fusion polypeptide of claim 1, wherein said fusion polypeptide is a pegylated fusion polypeptide. ### Claim 3 (depends on 2) The isolated chemokine-immunoglobulin fusion polypeptide of claim 2, wherein said pegylated fusion polypeptide has a molecular weight of at least about 500,000 daltons. ### Claim 4 (depends on 2) The isolated chemokine-immunoglobulin fusion polypeptide of claim 2, wherein said pegylated fusion polypeptide comprises PEG molecules having a collective molecular weight of at least about 20,000 daltons. ### Claim 5 (depends on 2) The isolated chemokine-immunoglobulin fusion polypeptide of claim 2, wherein said pegylated fusion polypeptide has a PEG-to-fusion polypeptide molar ratio of no more than about 10:1. ### Claim 6 (depends on 2) The isolated chemokine-immunoglobulin fusion polypeptide of claim 2, wherein said pegylated fusion polypeptide has a PEG-to-fusion polypeptide molar ratio of no more than about 5:1. ### Claim 7 (depends on 2) The isolated chemokine-immunoglobulin fusion polypeptide of claim 2, wherein said pegylated fusion polypeptide has a PEG-to-fusion polypeptide molar ratio of no more than about 2:1. ### Claim 8 (depends on 1) An isolated polynucleotide, encoding the chemokine-immunoglobulin fusion polypeptide of claim 1. ### Claim 9 (depends on 1) An expression vector, comprising: a regulatory element; and a polynucleotide operately linked to said regulatory element, wherein said polynucleotide encodes the chemokine-immunoglobulin fusion polypeptide of claim 1. ### Claim 10 (depends on 9) The expression vector of claim 9, wherein said vector is a plasmid-based expression vector. ### Claim 11 (depends on 9) The expression vector of claim 9, wherein said vector is a virus-based expression vector. ### Claim 12 (depends on 1) A pharmaceutical composition, comprising: the chemokine-immunoglobulin fusion polypeptide of claim 1; and a pharmaceutically acceptable carrier. ### Claim 13 (depends on 9) A composition, comprising: the expression vector of claim 9; and a pharmaceutically acceptable carrier.